263 related articles for article (PubMed ID: 15819981)
21. CDKN2A (P16(INK4a)) and CDK4 mutation analysis in 131 Australian melanoma probands: effect of family history and multiple primary melanomas.
Holland EA; Schmid H; Kefford RF; Mann GJ
Genes Chromosomes Cancer; 1999 Aug; 25(4):339-48. PubMed ID: 10398427
[TBL] [Abstract][Full Text] [Related]
22. Two p16 (CDKN2A) germline mutations in 30 Israeli melanoma families.
Yakobson E; Shemesh P; Azizi E; Winkler E; Lassam N; Hogg D; Brookes S; Peters G; Lotem M; Zlotogorski A; Landau M; Safro M; Shafir R; Friedman E; Peretz H
Eur J Hum Genet; 2000 Aug; 8(8):590-6. PubMed ID: 10951521
[TBL] [Abstract][Full Text] [Related]
23. Recurrent patterns of dual RB and p53 pathway inactivation in melanoma.
Yang G; Rajadurai A; Tsao H
J Invest Dermatol; 2005 Dec; 125(6):1242-51. PubMed ID: 16354195
[TBL] [Abstract][Full Text] [Related]
24. Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9.
Kumar R; Angelini S; Hemminki K
Oncogene; 2003 Dec; 22(58):9217-24. PubMed ID: 14681681
[TBL] [Abstract][Full Text] [Related]
25. Molecular characterization of human cutaneous melanoma-derived cell lines.
Ogbah Z; Puig-Butille JA; Simonetta F; Badenas C; Cervera R; Milá J; Benitez D; Malvehy J; Vilella R; Puig S
Anticancer Res; 2012 Apr; 32(4):1245-51. PubMed ID: 22493355
[TBL] [Abstract][Full Text] [Related]
26. Alterations in CDKN2A locus as potential indicator of melanoma predisposition in relatives of non-familial melanoma cases.
Levanat S; Situm M; Crnić I; Marasović D; Puizina-Ivić N; Pokupcić N; Musani V; Komar A; Kubat M; Furac I; Karija-Vlahović M; Krizanac S
Croat Med J; 2003 Aug; 44(4):418-24. PubMed ID: 12950144
[TBL] [Abstract][Full Text] [Related]
27. Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas.
Helsing P; Nymoen DA; Ariansen S; Steine SJ; Maehle L; Aamdal S; Langmark F; Loeb M; Akslen LA; Molven A; Andresen PA
Genes Chromosomes Cancer; 2008 Feb; 47(2):175-84. PubMed ID: 18023021
[TBL] [Abstract][Full Text] [Related]
28. Mutations of p16 and p15 tumor suppressor genes and replication errors contribute independently to the pathogenesis of sporadic malignant melanoma.
Matsumura Y; Nishigori C; Yagi T; Imamura S; Takebe H
Arch Dermatol Res; 1998 Apr; 290(4):175-80. PubMed ID: 9617435
[TBL] [Abstract][Full Text] [Related]
29. Novel germline p16 mutation in familial malignant melanoma in southern Sweden.
Borg A; Johannsson U; Johannsson O; Häkansson S; Westerdahl J; Mäsbäck A; Olsson H; Ingvar C
Cancer Res; 1996 Jun; 56(11):2497-500. PubMed ID: 8653684
[TBL] [Abstract][Full Text] [Related]
30. Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression.
Omholt K; Karsberg S; Platz A; Kanter L; Ringborg U; Hansson J
Clin Cancer Res; 2002 Nov; 8(11):3468-74. PubMed ID: 12429636
[TBL] [Abstract][Full Text] [Related]
31. Analysis of G(1)/S checkpoint regulators in metastatic melanoma.
Sauroja I; Smeds J; Vlaykova T; Kumar R; Talve L; Hahka-Kemppinen M; Punnonen K; Jansèn CT; Hemminki K; Pyrhönen S
Genes Chromosomes Cancer; 2000 Aug; 28(4):404-14. PubMed ID: 10862049
[TBL] [Abstract][Full Text] [Related]
32. Significant impact of promoter hypermethylation and the 540 C>T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase.
Straume O; Smeds J; Kumar R; Hemminki K; Akslen LA
Am J Pathol; 2002 Jul; 161(1):229-37. PubMed ID: 12107107
[TBL] [Abstract][Full Text] [Related]
33. The role of cell cycle regulatory proteins in the pathogenesis of melanoma.
Li W; Sanki A; Karim RZ; Thompson JF; Soon Lee C; Zhuang L; McCarthy SW; Scolyer RA
Pathology; 2006 Aug; 38(4):287-301. PubMed ID: 16916716
[TBL] [Abstract][Full Text] [Related]
34. Mutational analysis of the N-ras, p53, p16INK4a, CDK4, and MC1R genes in human congenital melanocytic naevi.
Papp T; Pemsel H; Zimmermann R; Bastrop R; Weiss DG; Schiffmann D
J Med Genet; 1999 Aug; 36(8):610-4. PubMed ID: 10465111
[TBL] [Abstract][Full Text] [Related]
35. CDKN2A mutations in multiple primary melanomas.
Monzon J; Liu L; Brill H; Goldstein AM; Tucker MA; From L; McLaughlin J; Hogg D; Lassam NJ
N Engl J Med; 1998 Mar; 338(13):879-87. PubMed ID: 9516223
[TBL] [Abstract][Full Text] [Related]
36. Molecular characterization of 9p21 deletions shows a minimal common deleted region removing CDKN2A exon 1 and CDKN2B exon 2 in diffuse large B-cell lymphomas.
Guney S; Bertrand P; Jardin F; Ruminy P; Kerckaert JP; Tilly H; Bastard C
Genes Chromosomes Cancer; 2011 Sep; 50(9):715-25. PubMed ID: 21638516
[TBL] [Abstract][Full Text] [Related]
37. Homozygous deletions of p16/MTS1 and p15/MTS2 genes are frequent in t(1;19)-negative but not in t(1;19)-positive B precursor acute lymphoblastic leukemia in childhood.
Ohnishi H; Hanada R; Horibe K; Hongo T; Kawamura M; Naritaka S; Bessho F; Yanagisawa M; Nobori T; Yamamori S; Hayashi Y
Leukemia; 1996 Jul; 10(7):1104-10. PubMed ID: 8683987
[TBL] [Abstract][Full Text] [Related]
38. Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets.
Walker GJ; Flores JF; Glendening JM; Lin AH; Markl ID; Fountain JW
Genes Chromosomes Cancer; 1998 Jun; 22(2):157-63. PubMed ID: 9598804
[TBL] [Abstract][Full Text] [Related]
39. Intragenic mutations of CDKN2B and CDKN2A in primary human esophageal cancers.
Suzuki H; Zhou X; Yin J; Lei J; Jiang HY; Suzuki Y; Chan T; Hannon GJ; Mergner WJ; Abraham JM
Hum Mol Genet; 1995 Oct; 4(10):1883-7. PubMed ID: 8595411
[TBL] [Abstract][Full Text] [Related]
40. Cloning and characterization of the CDKN2A and p19ARF genes from Monodelphis domestica.
Sherburn TE; Gale JM; Ley RD
DNA Cell Biol; 1998 Nov; 17(11):975-81. PubMed ID: 9839807
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
